The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1374
October 3, 2011
View Complete Issue         Table of Contents 2019 
Quetiapine (Seroquel) and QT-Interval Prolongation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Quetiapine (Seroquel) and QT-Interval Prolongation
October 3, 2011 (Issue: 1374)
The FDA has required the manufacturer of the secondgeneration antipsychotic quetiapine (Seroquel) to add a warning to the labeling saying that use of the drug should be avoided in combination with other drugs that prolong the electrocardiographic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Quetiapine (Seroquel) and QT-Interval Prolongation
Article code: 1374d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.